Drug Profile
SPP 1234
Alternative Names: SPP1234Latest Information Update: 16 Jul 2010
Price :
$50
*
At a glance
- Originator Speedel Group
- Developer Speedel
- Class Antihypertensives; Cardiovascular therapies
- Mechanism of Action Renin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hypertension
Most Recent Events
- 16 Jul 2010 Discontinued - Phase-0 for Hypertension in Switzerland (PO)
- 10 Jul 2008 Speedel Group has been acquired by Novartis
- 31 Mar 2008 Phase-0 for Hypertension in Switzerland (PO)